AFG2A
protein-codingAFG2 AAA ATPase homolog A, the group of AAA ATPases
Gene summary
This gene encodes a member of the ATPase associated with diverse activities family, whose members are defined by a highly conserved ATPase domain. Members of this family participate in diverse cellular processes that include membrane fusion, DNA replication, microtubule severing, and protein degradation. The protein encoded by this gene has a putative mitochondrial targeting sequence and has been proposed to function in maintenance of mitochondrial function and integrity during mouse spermatogenesis. Allelic variants in this gene have been associated with epilepsy, hearing loss, and cognitive disability syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2016]
- SPATA5
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~396.4 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0800439
Submitter: ClinGen
The *AFG2A* gene is located on chromosome 4 at 4q28.1 and encodes a member of the ATPase associated with diverse activities (AAA) protein family. *AFG2A* was first reported in connection with autosomal recessive syndromic complex neurodevelopmental disorder in 2015 (Tanaka et al., 2015 PMID: 26299366). Affected individuals are characterized by microcephaly, global developmental delay, intellectual disability, abnormal muscle tone, and sensorineural hearing impairment. Additional variable manifestations include epilepsy, cortical visual impairment, gastrointestinal disturbances, growth restriction, scoliosis, as well as immunodeficiency and thrombocytopenia. Brain imaging may show cerebral atrophy, thin corpus callosum, and hypomyelination. Twenty variants (11 missense, 5 nonsense, 2 frameshift, 1 canonical splice site, 1 deletion) reported in 18 probands across 2 publications are included in this curation (PMIDs: 29343804, 26299366). The mechanism of disease is reported to be loss-of-function. The maximum points for genetic evidence (12pts) was reached, however, additional cases are available in the literature (PMIDs: 34949788, 27246907). This gene-disease relationship is also supported by experimental evidence including functional alteration in non-patient cells and biochemical function (PMIDs: 29343804, 38554706). In summary, there is definitive evidence supporting the relationship between *AFG2A* and autosomal recessive syndromic complex neurodevelopmental disorder. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Syndromic Disorders GCEP on the meeting date July 23rd, 2024 (SOP Version 10).
Inheritance Pattern: AR
Disease ID:MONDO:0014698
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0014698
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0014698
Submitter: G2P
Inheritance Pattern: AR
Disease ID:MONDO:0014698
Submitter: PanelApp Australia
Clinical Genomic Database (CGD)
Manifestation: Allergy/Immunology/Infectious; Audiologic/Otolaryngologic; Hematologic; Neurologic
Intervention: Allergy/Immunology/Infectious; Audiologic/Otolaryngologic
Rationale: Although details are unclear, multiple individuals have been described as having immunodefiency, and awareness may allow prompt and aggressive treatment of infections; Among other findings, the condition can include sensorineural hearing loss, and some patients may benefit from early recognition and management of hearing loss
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to AFG2A variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_145207.3. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 4 | 196 | 1 | 201 | ||
| missense | 4 | 25 | 359 | 17 | 4 | 409 |
| nonsense | 22 | 9 | 1 | 32 | ||
| start loss | 2 | 2 | 4 | |||
| frameshift | 26 | 6 | 1 | 33 | ||
| splice donor/acceptor (+/-2bp) | 2 | 12 | 14 | |||
| Total | 54 | 54 | 367 | 213 | 5 | 693 |
Highest pathogenic variant AF is 0.00019176847
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_660208.2 | 16 | MANE Select | |
| Ensembl | ENSP00000274008.3 | 16 | MANE Select | |
| RefSeq | NP_001304728.1 | 11 | Standard | |
| RefSeq | NP_001332785.1 | 16 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Ribosome biogenesis in eukaryotes - Homo sapiens (human)
Biological Process
- spermatogenesis
- brain development
- cell differentiation
Molecular Function
- ATP binding
- ATPase activity
Cellular Component
- cytoplasm
- mitochondrion
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000274008
- Coding exons
- 16
- Length
- 396377
- Individuals with no LoFs
- 125625
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 123
- Defined
- 125748
- p
- 0.000489
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 0.460 | 446 | 474 | 0.941 | 0.0000232 | 5803 |
| Missense (PolyPhen) | 151 | 182.91 | 0.82556 | 2171 | ||
| Synonymous | 0.601 | 163 | 173 | 0.942 | 0.00000844 | 1790 |
| Loss of Function | 1.14 | 34 | 42.0 | 0.810 | 0.00000250 | 504 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00037 | 0.00037 | rare |
| Latino/Admixed American | 0.00023 | 0.00023 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.00050 | 0.00049 | rare |
| Finnish | 0.00028 | 0.00028 | rare |
| European (Non-Finnish) | 0.00071 | 0.00070 | rare |
| South Asian | 0.00033 | 0.00033 | rare |
| Other | 0.00066 | 0.00065 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: ATP-dependent chaperone which uses the energy provided by ATP hydrolysis to generate mechanical force to disassemble protein complexes. May be involved in morphological and functional mitochondrial transformations during spermatogenesis. {ECO:0000250|UniProtKB:P32794, ECO:0000250|UniProtKB:Q3UMC0}.;
- Disease
- DISEASE: Epilepsy, hearing loss, and mental retardation syndrome (EHLMRS) [MIM:616577]: An autosomal recessive disorder characterized by intellectual disability, intractable epilepsy, microcephaly, abnormal muscle tone, and sensorineural hearing loss. {ECO:0000269|PubMed:26299366}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.108
Intolerance Scores
- LoFtool
- 0.181
- RVIS EVS
- -0.22
- RVIS percentile EVS
- 37.66
Essentials
- Essential (CRISPR)
- E
- Essential (CRISPR2)
- E
- Essential (gene trap)
- E
- Indispensability pred.
- N
- Indispensability score
- 0.385
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |